Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc ACHFF


Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.


TSXV:ARCH - Post by User

Arch Biopartners Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(301)
•••
Post by Viking2233on Mar 27, 2024 3:34pm
135 Views
Post# 35956338

RJ Analyst

RJ AnalystNothing but total silence from our sole analyst at Raymond James. This analyst has not commented on number of material news releases:

1. Increased dosage study 

2. FDA Approval for New Phase 2 AKI trial

3. 6 sites for Turkey

4. 3 sites for Canada

5. First dosing commenced

6. Pre-IND meeting with FDA for new re-purposed drug with new phase 2 trial to commence in the fall of 2024

7. No dilution or additional funding required at this time

8. Funally the Independent 3rd Party Perr review was published 10 days ago, which analyst has been waiting for.

There is a lot of postive catalysts here for the analyst to digest, I see a bug upgrade coming in my opinion.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities